Summary
125.98 1.03(0.82%)05/14/2024
Dexcom Inc (DXCM)
Dexcom Inc (DXCM)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.24 | 2.03 | -7.13 | 2.61 | 36.53 | 8.14 | 334.65 | 4,320.41 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 129.96 | |
| Open | 129.60 | |
| High | 130.32 | |
| Low | 129.04 | |
| Volume | 938,345 | |
| Change | 0.32 | |
| Change % | 0.24 | |
| Avg Volume (20 Days) | 2,321,361 | |
| Volume/Avg Volume (20 Days) Ratio | 0.40 | |
| 52 Week Range | 74.75 - 142.00 | |
| Price vs 52 Week High | -8.48% | |
| Price vs 52 Week Low | 73.86% | |
| Range | 0.28 | |
| Gap Up/Down | -0.34 | |
Fundamentals | ||
| Market Capitalization (Mln) | 50,526 | |
| EBIDTA | 848,499,968 | |
| PE Ratio | 82.5000 | |
| PEG Ratio | 2.5317 | |
| WallStreet Target Price | 153.37 | |
| Book Value | 5.6720 | |
| Earnings Per Share | 1.5400 | |
| EPS Estimate Current Quarter | 0.2700 | |
| EPS Estimate Next Quarter | 0.3900 | |
| EPS Estimate Current Year | 1.7900 | |
| EPS Estimate Next Year | 2.2600 | |
| Diluted EPS (TTM) | 1.5400 | |
| Revenues | ||
| Profit Marging | 0.1682 | |
| Operating Marging (TTM) | 0.1098 | |
| Return on asset (TTM) | 0.0679 | |
| Return on equity (TTM) | 0.2854 | |
| Revenue TTM | 3,801,799,936 | |
| Revenue per share TTM | 9.8270 | |
| Quarterly Revenue Growth (YOY) | 0.2420 | |
| Quarterly Earnings Growth (YOY) | 1.9870 | |
| Gross Profit (TTM) | 1,883,100,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 82.5000 | |
| Forward PE | 77.5194 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 25.3774 | |
| Revenue Enterprise Value | 14.4564 | |
| EBITDA Enterprise Value | 57.1240 | |
| Shares | ||
| Shares Outstanding | 397,684,000 | |
| Shares Float | 393,770,628 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.03 | |
| Insider (%) | 0.35 | |
| Institutions (%) | 99.75 | |
05/13 13:30 EST - Seeking Alpha
Dexcom: Positive Catalysts Ahead To Support Growth
Dexcom is a buy despite a recent slowdown in US sales. The upcoming launch of Stelo, a glucose monitor for non-insulin users, has a large potential market and is expected. Ex-US growth remains strong at 26%, and conservative management guidance suggests confidence in future performance. Historically, Dexcom has exceeded revenue guidance. Lower than expected adoption of Stelo and challenges in the Japan sales model transition are potential risks.
Dexcom: Positive Catalysts Ahead To Support Growth
Dexcom is a buy despite a recent slowdown in US sales. The upcoming launch of Stelo, a glucose monitor for non-insulin users, has a large potential market and is expected. Ex-US growth remains strong at 26%, and conservative management guidance suggests confidence in future performance. Historically, Dexcom has exceeded revenue guidance. Lower than expected adoption of Stelo and challenges in the Japan sales model transition are potential risks.
05/13 08:45 EST - The Motley Fool
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Moderna has a deep pipeline that should help it land brand-new approvals regularly. DexCom has a massive opportunity in the vast continuous glucose monitoring market.
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Moderna has a deep pipeline that should help it land brand-new approvals regularly. DexCom has a massive opportunity in the vast continuous glucose monitoring market.
05/06 03:26 EST - Seeking Alpha
DexCom: Attractive Discount After Strong Earnings Results
DexCom shares took a slight tumble after earnings were announced Thursday evening off of strong results. Guidance for the year was upgraded due to growing demand and FDA clearance for the Apple Watch as a primary display for blood sugars. Despite concerns over timing and other risks, I believe there will be sustained revenue growth and that there is potential for long-term price accretion.
DexCom: Attractive Discount After Strong Earnings Results
DexCom shares took a slight tumble after earnings were announced Thursday evening off of strong results. Guidance for the year was upgraded due to growing demand and FDA clearance for the Apple Watch as a primary display for blood sugars. Despite concerns over timing and other risks, I believe there will be sustained revenue growth and that there is potential for long-term price accretion.
04/30 13:45 EST - Zacks Investment Research
Here is Why Growth Investors Should Buy DexCom (DXCM) Now
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here is Why Growth Investors Should Buy DexCom (DXCM) Now
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
04/30 10:00 EST - Zacks Investment Research
DexCom, Inc. (DXCM) Is a Trending Stock: Facts to Know Before Betting on It
DexCom (DXCM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
DexCom, Inc. (DXCM) Is a Trending Stock: Facts to Know Before Betting on It
DexCom (DXCM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
04/26 08:30 EST - Zacks Investment Research
DexCom (DXCM) Q1 Earnings Beat, Strong CGM Demand Continues
DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
DexCom (DXCM) Q1 Earnings Beat, Strong CGM Demand Continues
DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
04/25 19:36 EST - Seeking Alpha
DexCom, Inc. (DXCM) Q1 2024 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM ) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance, and Investor Relations Kevin Sayer - Chairman, President, and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Conference Call Participants Danielle Antalffy - UBS Securities Robbie Marcus - J.P. Morgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citibank Jeff Johnson - Robert W.
DexCom, Inc. (DXCM) Q1 2024 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM ) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance, and Investor Relations Kevin Sayer - Chairman, President, and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Conference Call Participants Danielle Antalffy - UBS Securities Robbie Marcus - J.P. Morgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citibank Jeff Johnson - Robert W.
04/25 19:01 EST - Zacks Investment Research
DexCom (DXCM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
DexCom (DXCM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
04/24 10:32 EST - Zacks Investment Research
Wall Street Bulls Look Optimistic About DexCom (DXCM): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Wall Street Bulls Look Optimistic About DexCom (DXCM): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
04/22 10:22 EST - Zacks Investment Research
Ahead of DexCom (DXCM) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for DexCom (DXCM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Ahead of DexCom (DXCM) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for DexCom (DXCM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
04/18 09:31 EST - Zacks Investment Research
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
04/15 12:21 EST - Zacks Investment Research
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth.
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth.
04/15 11:56 EST - Zacks Investment Research
DexCom (DXCM), MD Revolution Unite to Boost Diabetes Management
DexCom (DXCM) and MD Revolution collaborate to integrate Dexcom's continuous glucose monitoring systems with MD Revolution's remote care management platform to boost remote diabetes management.
DexCom (DXCM), MD Revolution Unite to Boost Diabetes Management
DexCom (DXCM) and MD Revolution collaborate to integrate Dexcom's continuous glucose monitoring systems with MD Revolution's remote care management platform to boost remote diabetes management.
04/11 14:22 EST - Schwab Network
SLB, DXCM, CRH: The Economy is Relatively Healthy
Economic trends and earnings continue to drive most of the conversations, notes Tyler Ellegard. He discusses the impact upcoming earnings could have on the markets.
SLB, DXCM, CRH: The Economy is Relatively Healthy
Economic trends and earnings continue to drive most of the conversations, notes Tyler Ellegard. He discusses the impact upcoming earnings could have on the markets.
04/11 10:46 EST - Zacks Investment Research
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.
04/11 09:02 EST - Seeking Alpha
DexCom Is Pricey For A Reason - Its Growth Story Reflects That
DexCom received FDA approval for its continuous glucose monitoring product, Stelo, to be available over the counter, making it the first OTC CGM product ever. The company has demonstrated robust growth in revenue and operating income, warranting its high valuation multiples. DexCom has strong growth catalysts, including the launch of Stelo, which is expected to contribute to significant revenue growth in the future.
DexCom Is Pricey For A Reason - Its Growth Story Reflects That
DexCom received FDA approval for its continuous glucose monitoring product, Stelo, to be available over the counter, making it the first OTC CGM product ever. The company has demonstrated robust growth in revenue and operating income, warranting its high valuation multiples. DexCom has strong growth catalysts, including the launch of Stelo, which is expected to contribute to significant revenue growth in the future.
04/10 16:00 EST - InvestorPlace
Nasdaq Nightmares: 3 Stocks to Sell Before Reality Sets In
The latest employment figures saw indices rise. However, losses earlier in the week persist as investors remain cautious of the Fed's stance on interest rate adjustments.
Nasdaq Nightmares: 3 Stocks to Sell Before Reality Sets In
The latest employment figures saw indices rise. However, losses earlier in the week persist as investors remain cautious of the Fed's stance on interest rate adjustments.
04/10 09:27 EST - Market Watch
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
04/08 19:06 EST - Zacks Investment Research
Why the Market Dipped But DexCom (DXCM) Gained Today
In the most recent trading session, DexCom (DXCM) closed at $139.94, indicating a +0.73% shift from the previous trading day.
Why the Market Dipped But DexCom (DXCM) Gained Today
In the most recent trading session, DexCom (DXCM) closed at $139.94, indicating a +0.73% shift from the previous trading day.
04/04 10:01 EST - Zacks Investment Research
DexCom, Inc. (DXCM) is Attracting Investor Attention: Here is What You Should Know
DexCom (DXCM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
DexCom, Inc. (DXCM) is Attracting Investor Attention: Here is What You Should Know
DexCom (DXCM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.